Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-30.07M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -284.97% |
| Return on Assets (Trailing 12 Months) | -170.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.79 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.39 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.91 |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 5.23M |
| Free Float | 4.42M |
| Market Capitalization | $0.25M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 1.80 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 44.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |